The role of prebiotics and synbiotics in critically ill patients

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 6, 2008, Pages 782-789

  Manzanares, William ^a,c   Hardy, Gil ^b  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^b MASSEY UNIVERSITY   (New Zealand)

^c HOSPITAL DE CLÍNICAS   (Uruguay)

Author keywords

Critically ill patient; Fibre; Prebiotic; Synbiotic

Indexed keywords

ANTIBIOTIC AGENT; BETA GLUCAN; FRUCTOSE OLIGOSACCHARIDE; GALACTOSE OLIGOSACCHARIDE; INULIN; LACTULOSE; MALTODEXTRIN; NUTRISON MULTI FIBRE; PECTIN; PLACEBO; PREBIOTIC AGENT; STARCH; SYNBIOTIC 2000 FORTE; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ACUTE PANCREATITIS; BACTERIAL TRANSLOCATION; BRAN; BURN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENTERIC FEEDING; FIBER; HUMAN; INFECTION; INFECTION PREVENTION; INFLAMMATION; INTENSIVE CARE UNIT; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; INTESTINE OBSTRUCTION; LIVER TRANSPLANTATION; MICROBIAL COMMUNITY; MONOTHERAPY; MULTIPLE ORGAN FAILURE; MULTIPLE TRAUMA; OAT; PANCREATITIS; PERITONITIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; REVIEW; SEPSIS;

CRITICAL ILLNESS; DIETARY FIBER; DRUG SYNERGISM; GASTROINTESTINAL TRACT; HEALTH FOOD; HUMANS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; NUTRITIVE VALUE; PROBIOTICS;

EID: 55149085921     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328312c4f9     Document Type: Review

References (66)

1. Bengmark S. Bioecological control of perioperative and ITU morbidity. Langenbecks Arch Surg 2004; 389:145-154.
2. Marshall JC, Christou NV, Meakins JL The gastrointestinal tract: the undrainded abscess of multiple organ failure. Ann Surg 1993; 218:111-119.
3. Farthing MJG. Bugs and the gut: an unstable marriage. Best Pract Res Clin Gastroenteral 2004; 18:233-239.
4. Alverdy JC, Laughlin RS, Wu L. Influence of the critically ill state on hostpathogen interactions within the intestine: gut-derived sepsis redefined. Crit Care Med 2003; 31:598-607.
5. Gibson GR, Roberfroid MB. Dietary modulation of the colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125:1401-1412.
6. Gibson GR, Probert HM, Van Loo J, et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotic. Nutr Res Rev 2004; 17:259-275.
7. Robertfroid M. Prebiotics: the concept revisited. J Nutr 2007; 137:8308-M 837S. An excellent and comprehensive update about the concept of prebiotics that introduces the concept of prebiotic index and summarizes the effects of various oligosaccharides.
8. Kolida S, Gibson GR. Prebiotic capacity of inulin-type fructans. J Nutr 2007; 127:25038-25068. This critical review discusses the types of prebiotics and especially the prebiotic capacity of inulin-type fructans, including in-vitro and in-vivo studies on the prebiotic effect of fructans.
9. Bengmark S. Synbiotics and the mucosal barrier in critically ill patients. Curr Opin Gastroenteral 2005; 21:712-716.
10. Klessen B, Blaut M. Modulation of the gut mucosal biofilm. Br J Nutr 2005; 93 Suppl 1:S35-S40.
11. Gibson GR, McCartney AL, Rastall RA. Prebiotics and resistance to gastrointestinal infections. Br J Nutr 2005; 93 Suppl 1:S31 -S34.
12. Van Loo J. The specificity of the interaction with intestinal bacteria fermentation by prebiotics determines their physiological efficacy. Br J Nutr 2004; 17:89-98.
13. Bengmark S. Bioecological control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics. Gastroenterol Clin N Am 2005; 34:413-436.
14. Bengmark S. Gut microbial ecology in critical illness: is there a role for prebiotics, probiotics and synbiotics? Curr Opin Crit Care 2002; 8:145-151.
15. Bengmark S. Bioecological control of inflammation and infection in critical illness. Anesthesiol Clin North America 2006; 24:299-323.
16. Oliveira Fuster G, Gonzalez-Molero I. Probiotics and prebiotics in clinical practice. Nutr Hosp 2007; 22 Suppl 2:26-34.
17. Bengmark S, Martindale R. Prebiotics and synbiotics in clinical medicine. Nutr Clin Pract 2005; 20:244-261.
18. Bengmark S, Gil A. Bioecological and nutritional control of disease: prebiotics, probiotics and synbiotics. Nutr Hosp 2006; 21:73-86.
19. Guarner F. Studies with inulin-type fructans in intestinal infections, permeability and inflammation. J Nutr 2007; 137:2568S-2571S. An excellent review that analyzes experimental and clinical studies about the effects of inulin and oligofructose on gut mucosal barrier, intestinal and systemic infections.
20. Mcfarlane S, Macfarlane GT, Cummings JH. Prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006; 24:701-714.
21. Bruzzese E, Volpicelli M, Squaglia M, et al. Impact of prebiotics on human health. Dig Liver Dis 2006; 38 Suppl 2:S283-S287.
22. Roy CC, Kien CL, Bouthiller L, et al. Short chain fatty acids: ready for prime time? Nutr Clin Pract 2006; 21:351-366.
23. Morrison DJ, Mackay WG, Edwards CA, et al. Butyrate production from oligofructose fermentation by the human faecal flora: what is the contribution of extracellular acetate and lactate? Br J Nutr 2006; 96:570-577.
24. Forchielli ML, Walker WA. The rale of gut-associated lymphoid tissues and mucosal defence. Br J Nutr 2005; 93 Suppl 1:S41-S48.
25. Watzl B, Girrbach S, Roller M. Inulin, oligofructose and immunomodulation. Br J Nutr 2005; 93 Suppl 1 :S49-S55.
26. Guarner F. Inulin and oligofructose: impact on intestinal diseases and disorders. Br J Nutr 2005; 93 Suppl 1:S61-S65.
27. Chen YS, Srionnual S, OndaT, et al. Effects of prebiotic oligosaccharides and trehalose on growth and production of bacteriocins by lactic acid bacteria. Lett Appl Microbiol 2007; 45:190-193.
28. Roller M, Reckemmer G, Watzl B. Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rat. J Nutr 2004; 134:153-156.
29. MacFie J, Reddy BS, Gatt M, et al. Bacterial translocation studied in 927 patients over 13 years. Br J Surg 2006; 46:313-319.
30. Langlands SJ, Hopkins MJ, Coleman N, et al. Prebiotics carbohydrates modify the mucosa-associated microflora of the human large bowel. Gut 2004; 53:1610-1616.
31. Su P, Henriksson A, Mitchell H. Selected prebiotics support the growth of probiotic mono-cultures in vitro. Anaerobe 2007; 13:134-139.
32. Su P, Henriksson A, Mitchell H. Prebiotics enhance survival and prolong the retention period of specific probiotic inocula in an in vivo murin model. J Appl Microbiol 2007; 103:2392-2400.
33. Klarin B, Johansson MN, Molin G, et al. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Crit Care 2005; 9:R285-R293.
34. Jain PK, McNaught CE, Anderson ADG, et al. Influence of synbiotic containing Lactobacillus acidophilus LA5, Bifidobacterium lactis BP12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomized controlled trial. Clin Nutr 2004; 23:467-475.
35. Rayes N, Hansen S, Boucsein K, et al. Early enteral supply of fiber and lactobacilli vs. parenteral nutrition: a controlled trial in major abdominal surgery patients. Nutrition 2002; 18:609-615.
36. Spindler-Vesel A, Bengmark S, Vovk I, et al. Synbiotics, prebiotics, or peptide in early enteral nutrition: a randomized study in trauma patients. JPEN J Parenter Enterai Nutr 2007; 31:119-126. A randomized study comparing synbiotic, prebiotic fibre, enteral glutamine and peptides on intestinal permeability and nosocomial infections.
37. Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, et al. Benefits of a synbiotic formula (Synbiotic 2000 Forte) in critically ill trauma patients: early results of a randomized controlled trial. World J Surg 2006; 30:1848-1855.
38. Gomersall CD, Joynt GM, Leung P, et al. Does routine administration of probiotics improve outcome in critically ill patients [abstract], ANZCA ASM; 2006.
39. Ammori BJ. Role of the gut in the course of severe acute pancreatitis. Pancreas 2003; 26:122-129.
40. Oláh A, Bélagyi T, Issekutz A, et al. Randomized clinical trial of specific lactobacillus and fibre supplement early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002; 9:1103-1107.
41. Weale R, Edwards A. Letter 1: Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2003; 90:122-123.
42. Rahman SH, Catton JA, McMahon MJ. Letter 2: Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2003; 90:123.
43. Oláh A, Bélagyi T, Pótó L, et al. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology 2007; 54:590-594.
44. Bengmark S. Bioecological control of acute pancreatitis: the role of enteral nutrition, proandsynbiotics. Curr Opin Clin Nutr Metab Care 2005;8:557-561.
45. Lochs H, Allison SP, Meier R, et al. Introductory to the ESPEN guidelines on enteral nutrition: terminology, definitions and general topics. Clin Nutr 2006; 25:180-186.
46. Karakan T, Ergun M, Dogan I, et al. Comparison of early enteral nutrition in severe acute pancreatitis with prebiotic fiber supplementation versus standard enteral solution: a prospective randomized double blind study. World J Gastroenterol 2007; 13:2733-2737. This study is the first to compare single use of prebiotics vs. standard early enteral nutrition in SAP.
47. Besselink MGH, van Stanvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:651-659. So far, the most important and well designed study of probiotics supplementation in predicted severe pancreatitis. Its results suggest that probiotics, but not prebiotics, may be unsafe in ICU patients, especially in those patients at risk of nonocclusive intestinal ischaemia.
48. Ridwan BU, Konong CJM, Besselink MGH, et al. Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. Lett Appl Microbiol 2008; 46:61-67.
49. Sheldon T. Dutch trial of probiotics in acute pancreatitis is to be investigated after deaths. BMJ 2008; 336:296-297.
50. Rayes N, Hansen S, Seehofer D, et al. Early enterai supply of Lactobacillus and fibre vs. selective bowel decontamination (SBD): a controlled trial in liver transplant recipients. Transplantation 2002; 74:123-127.
51. Rayes N, Seehofer D, Theruvath T, et al. Combined perioperative enteral supply of bioactive pre and probiotics abolishes postoperative bacterial infections in human liver transplantation: a randomised, double-blind clinical trial. Am J Transplant 2005; 5:125-130.
52. Bengmark S. Synbiotic control of inflammation and infection in transplantation. Transplant Rev 2004; 18:38-53.
53. Deitch EA. Intestinal permeability is increased in burn patients shortly after injury. Surgery 1990; 107:411-416.
54. Olguin F, Araya M, Hirsch S, et al. Prebiotic ingestion does not improve gastrointestinal barrier function in burn patients. Burns 2005; 31:482-488.
55. Presier JC, Berre J, Carpentier Y, et al. Management of nutrition in European Intensive Care Units. Results of questionnaire. Working group on Metabolism and Nutrition of the European Society of Intensive Care Medicine, Int Care Med 1999; 25:95-101.
56. Whelan K. Enteral-tube feeding diarrhoea: manipulating the colonic microbiota with probiotics and prebiotics. Proc Nutr Soc 2007; 66:299-306. A comprehensive review summarizing the effects of probiotics and prebiotics as preventive and therapeutic agents in ETF diarrhoea.
57. Rushdi TA, Richard C, Khater YH. Control of diarrhea by fiber-enriched diet in ICU patients on enteral nutrition: a prospective randomized controlled trial. Clin Nutr 2004; 23:1344-1352.
58. Spapen H, Diltoer M, Van Malderen C, et al. Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective, double blind, randomized and controlled trial. Clin Nutr 2001; 20:301-305.
59. Bosscher D, Van Loo J. Inulin and oligofructose as prebiotics in the prevention of intestinal infections and diseases. Nutr Res Rev 2006; 19:216-226.
60. Mac Farland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-822.
61. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3:442-448.
62. Lewis S, Burmeister S, Brazier J. Failure of dietary oligofructose to prevent antibiotic-associated diarrhea. Aliment Pharmacol Ther 2005; 21:469-477.
63. de Vrese M, Marteau PR. Probiotics and prebiotics. Effects on diarrhea. J Nutr 2007; 137:8035-8113. An important analysis of the effects of probiotics and prebiotics on diarrhoea, concluding that with the exception of AAD, studies are not yet sufficient to recommend the use of synbiotics in the treatment of diarrhoea.
64. Bengmark S. Aggressive management of surgical emergencies. Ann R Coll Surg Engl 2006; 88:624-629.
65. Watkinson PJ, Barber VS, Dark P, Young JD. The use of pre- pro- and synbiotic in adult intensive care unit patients: systematic review. Clin Nutr 2007; 26:182-192.
66. Heyland DK, Dhaliwal R, Drover J, et al. Canadian Clinical Practice Guidelines for nutrition support in mechanically ventilated, critically ill ventilated patients. Update 2007. http://www.criticalcarenutrition.com.